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Abstract
Background: Clopidogrel bisulfate is an antiplatelet agent used to prevent ischaemic events in patients with vascular
disease. Current guidelines recommend withholding clopidogrel for 7 days pre-operatively. However these are not based
on orthopaedic patients. We therefore decided to survey current orthopaedic practice to see whether this complied
with available clinical data.
Method: A questionnaire was sent to all orthopaedic consultants in Scotland.
Four haematology departments, and the manufacturers, were contacted to ask for their recommendations, and a
database search was performed.
Results: 140 questionnaires were sent with a 60.7% response. 84.7% of respondents have encountered patients on
clopidogrel. Of those, 13.9% did not routinely stop it, and 86.1% stopped it 5–21 days pre-operatively (47.2% at 7 days).
45.9% had a unit policy on stopping clopidogrel, and the majority (69.4%) did not consult their haematology department
prior to instituting their policy.
Increased peri-operative bleeding was the most reported complication (22.6%). However this was only noted in those
who stopped clopidogrel greater-than 7 days pre-operatively.
Haematology advice ranged from continuing clopidogrel peri-operatively to stopping it 7 days pre-operatively and
starting low-molecular-weight-heparin for thrombo-prophylaxis. The manufacturers suggested stopping clopidogrel 7
days pre-operatively. An internet search did not reveal any data on the effect of clopidogrel peri-operatively in
orthopaedic patients.
Discussion: Recommendations on stopping clopidogrel have evolved from studies conducted on patients undergoing
cardio-thoracic surgery. There is no data available on the effect of clopidogrel in orthopaedic practice. Our survey
indicates that increased bleeding has not been found in patients who continue clopidogrel peri-operatively.
Almost half of respondents complied with current recommendations, stopping clopidogrel 7 days pre-operatively.
However there remains a lack of consensus amongst orthopaedic surgeons.
Currently elective patients should stop clopidogrel 7 days pre-operatively, and emergency patients should stop 
clopidogrel on admission, however their operation should not be delayed due to clopidogrel usage.
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Background
Clopidogrel bisulfate (Plavix®) is an antiplatelet agent that
is used in the secondary prevention of ischaemic events in
patients with ischaemic heart disease or peripheral vascu-
lar disease that are intolerant of aspirin, or in those who
require additional antiplatelet therapy in combination
with aspirin [1].
Atherosclerotic disease of both peripheral and central
arteries is extremely common in the British population
[2]. Combination therapy with statins and antiplatelet
agents such as aspirin and clopidogrel is increasingly
being used to combat the morbidity and mortality associ-
ated with these conditions [3]. Therefore, it is probable
that more patients presenting to hospital for elective or
emergency orthopaedic surgery will be on an antiplatelet
agent. For patients taking the antiplatelet agent aspirin,
current Scottish Intercollegiate Guidelines Network
(SIGN) recommendations state that aspirin can be contin-
ued peri-operatively and used as deep venous thrombosis
(DVT) prophylaxis [4]. There is however no SIGN recom-
mendation for patients taking clopidogrel.
We have audited the current orthopaedic practice in Scot-
land with regards to patients taking clopidogrel admitted
both in the trauma and elective setting. Our aim in this
study was to compare current practice with evidence based
recommendations, the pharmaceutical industry advice,
and haematology advice, in order to ascertain whether or
not there was a consensus. We highlight the need to
develop a uniform protocol based on current best evi-
dence in dealing with these patients.
Methods
A standardised anonymous questionnaire was sent to all
practising orthopaedic consultants in Scotland (Fig 1).
They were requested to return the completed question-
naire to the first author. The haematology departments at
all four Scottish university teaching hospitals (Edinburgh
Royal Infirmary (ERI), Glasgow Royal Infirmary (GRI),
Aberdeen Royal Infirmary (ARI), and Dundee Ninewells
Hospital), were also contacted to establish whether they
had any advice regarding management of orthopaedic
patients taking clopidogrel.
The pharmaceutical company responsible for manufactur-
ing Plavix ® (Bristol-Myers Squibb) was contacted to see
whether they had any recommendations specific to ortho-
paedic patients, and to ascertain if any research had been
conducted in order to support their recommendations.
The current British National Formulary (BNF 51) recom-
mendation was also noted, and a review of available liter-
ature was performed through google, pub med, medline,
and Cochrane database searches.
Results
One hundred and forty questionnaires were sent, with a
60.7% response rate (85 replies). 84.7% of respondents
had encountered patients on clopidogrel in their routine
practice. There was wide variation in management
between different respondents. Almost half (47.2%)
stopped clopidogrel 7 days pre-operatively (Table 1),
while 13.9% did not routinely stop the medication. The
remaining 38.9% stopped the medication at a variable
interval between 5 days and 21 days before surgery. No
comment was made as to whether or not the decision to
stop clopidogrel, and if so when, was based on urgency of
surgery (ie. trauma or elective procedures). Two consult-
ants who had not personally encountered patients on
clopidogrel said they would ideally discontinue the med-
ication 7 days pre-operatively.
Increased peri-operative complications were reported by
more than one quarter (25.8%) of respondents (Table 2),
the most common of which was increased intra-operative
and post-operative bleeding (22.6%). Less than half of
respondents (45.9%) stated that there was a unit policy in
place on whether or not clopidogrel should be stopped. In
Clopidogrel Audit Letter Figure 1
Clopidogrel Audit Letter.
Clopidogrel Audit (letter sent to Consultants) 
 
Dear Sir / Madam : 
 
Clopidogrel (Plavix) is used for primary and secondary prevention of vascular ischaemic 
events in those intolerant of aspirin or if additional therapy is required. Its use has been 
increasing over the past few years. 
 
A known side-effect is increased risk of bleeding from wounds, but there is no 
widespread data available on whether or not it increases operative blood loss, and if or 
when it should be stopped pre-operatively. For this reason we are conducting a national 
survey of Orthopaedic consultant practice with regards to stopping clopidogrel pre-
operatively in elective and emergency cases. We would be grateful if you could take the 
time to fill in this questionnaire and return it in the self-addressed envelope. 
 
Q1.  Have you encountered any elective / emergency patients taking clopidogrel ? 
  Y e s   ⁫     N o   ⁫  
 
Q .  Do you routinely stop clopidogrel pre-operatively ? 
  Y e s   ⁫     N o   ⁫  
  If Yes when -    1 week ⁫   weeks ⁫  Other…….. 
 
Q3.  What do you use for DVT prophylaxis in these patients -  None ⁫ 
         A s p i r i n   ⁫  
         C l e x a n e   ⁫  
         O t h e r   ⁫  
 
Q4.  Is there a department policy on stopping clopidogrel ? 
  Y e s   ⁫     N o   ⁫  
 
Q5.  Was this discussed with your haematology department ? 
  Y e s   ⁫     N o   ⁫  
 
Q6.  Do you think further guidelines detailing when to stop clopidogrel pre-
  operatively would be useful ? 
  Y e s   ⁫     N o   ⁫  
 
Q7.  Have you ad any peri-operative complications with patients taking  
 clopidogrel  ?   Yes  /  No 
  If Yes specify……… 
 
Thankyou for your time. All results will remain confidential. Thrombosis Journal 2007, 5:6 http://www.thrombosisjournal.com/content/5/1/6
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addition, the majority (69.4%) did not seek specific hae-
matology advice prior to instituting their policy on stop-
ping the medication. The vast majority (70.6%) felt
further guidelines would be useful.
We obtained recommendations from all four Scottish uni-
versity teaching hospital haematology departments
regarding the peri-operative management of orthopaedic
patients taking clopidogrel (Table 3). All four haematol-
ogy departments suggested that a cardiology opinion
should be sought prior to altering medication, and that
the decision whether or not to stop clopidogrel depends
on the balance between risks of bleeding compared to the
risk of an ischemic event. Most haematologists felt that
clopidogrel should ideally be stopped before planned sur-
gery and that if additional DVT prophylaxis was needed
(high risk patients), low molecular weight heparin
(LMWH) or fondaparinux should be used. Discontinuing
clopidogrel, and commencing these patients on aspirin
(as many orthopaedic units use low dose aspirin as their
standard DVT prophylaxis) was not thought to be advisa-
ble, as this does not allow platelet function to recover. For
those taking aspirin and clopidogrel together, it was sug-
gested that aspirin could be continued as DVT prophylaxis
if indicated once clopidogrel was stopped. In the trauma
setting, there was a difference of opinion as to what the
best practice should be with suggestions that it may be
possible to continue clopidogrel during the peri-operative
period utilising its anti-platelet action for thrombo-
prophylaxis.
The manufacturers of clopidogrel, Bristol-Myers Squibb
(UK), were of the opinion that if an antiplatelet effect is
not desired, clopidogrel should be stopped 7 days in
advance of surgery. However no studies were undertaken
specifically on orthopaedic patients. The current volume
of the BNF states that clopidogrel should be stopped 7
days pre-operatively [5]. There was no specific advice for
orthopaedic patients. Literature review did not reveal any
published data on the effect of continuing or discontinu-
ing clopidogrel in orthopaedic elective and trauma
patients. There was also no data available on using clopi-
dogrel as peri-operative DVT prophylaxis in orthopaedic
patients.
Discussion
Clopidogrel is an antiplatelet agent that is being increas-
ingly prescribed in both general practice and hospital
medicine due to its synergistic action with aspirin, and
also for those intolerant of aspirin. The mechanism of
action is by irreversibly inhibiting binding of adenosine
diphosphate (ADP) to its platelet receptor. This inhibits
ADP-mediated activation of glycoprotein IIb/IIIa com-
plex. This in turn inhibits platelet aggregation [1]. As the
receptor modification is irreversible, platelet aggregation
is impaired for the remainder of the platelets lifespan,
generally 7 days. It is because of this permanent effect that
the manufacturers, and the current BNF guidelines, rec-
ommend stopping clopidogrel 7 days in advance of elec-
tive surgery if the antiplatelet effect is not desired [5].
Therefore current practice for the majority reflects the cur-
rent recommendation.
This recommendation however was based on studies that
showed increased rate of post-operative bleeding, need for
transfusion, and re-operation rate in patients undergoing
cardiothoracic surgery that had clopidogrel continued
pre-operatively [6-9]. To our knowledge there has been no
research into continued use of clopidogrel peri-opera-
tively in orthopaedic patients.
Patients undergoing orthopaedic surgery have a high inci-
dence of thrombo-embolic complications [10], especially
if no DVT prophylaxis is used [11]. DVT prophylaxis can
be both mechanical and pharmacological, and both
methods have been shown to decrease thrombo-embolic
phenomena in orthopaedic patients [12-14]. Although
the new National Institute for Clinical Excellence (NICE)
guidelines do not mention it [15], the Scottish Intercol-
Table 2: Perioperative complications in patients taking clopidogrel
Do you routinely 
stop clopigorel
Have you found increased peri-operative 
complications in patients taking clopidogrel
Complications encountered
Yes (62) Yes – 16 (25.8%) Bleeding – 14 (22.6%) Haematoma – 2 (3.2%) Wound infection – 2 
(3.2%) CVE * – 1 (1.6%)
No – 46 (74.2%) N/A
No (10) No – 10 (100%) N/A
* CVE – Cerebro-Vascular Event
Table 1: When do you routinely stop clopidogrel
When Do You Stop Clopidogrel Number (%)
Do not stop 10 (13.9%)
5 days 1 (1.4%)
7 days 34 (47.2%)
10 days 4 (5.6%)
14 days 17 (23.6%)
21 days 1 (1.4%)
No time given 5 (6.9%)Thrombosis Journal 2007, 5:6 http://www.thrombosisjournal.com/content/5/1/6
Page 4 of 5
(page number not for citation purposes)
legiate Guidelines Network (SIGN guidelines) suggests
that one method of DVT prophylaxis is aspirin [4]. This
was also supported by one of the haematology depart-
ments we contacted. It has been shown that aspirin
reduces the risk of thrombo-embolic disease, and that the
risk of increased postoperative bleeding, haematoma, or
infection is low [13]. Therefore we pose the question that
although the mechanism of action of both aspirin and
clopidogrel is different (aspirin inhibits the cyclo-oxygen-
ase dependent production of thromboxane A2); if aspirin
has been shown to be a safe and effective method of DVT
prophylaxis in orthopaedic patients could clopidogrel not
be used in patients already taking the medication? Cur-
rently there appears to be no data available to support this
and clopidogrel is not currently licensed for use in DVT
prophylaxis.
In our survey 13.9% of respondents did not routinely stop
clopidogrel pre-operatively. None of these respondents
reported any increased incidence of pre-operative or post-
operative complications. This anecdotally seems to sug-
gest that continued use of clopidogrel in patients under-
going orthopaedic surgery may not result in increased risk
of complications such as bleeding. This is however con-
trasted by the reports of increased peri-operative compli-
cations (namely bleeding) in those who stop the
medication pre-operatively. The finding of increased com-
plications attributable to clopidogrel in those who stop
the medication compared with those who do not is para-
doxical. There is no literature available to suggest a
rebound coagulopathy in patients' that stop clopidogrel
pre-operatively. Indeed the likely alternative explanation
is that as assessment of bleeding is subjective, consultants
who are aware of the complications of clopidogrel may
attribute any bleeding to the medication despite having
stopped it for a period greater than its' supposed physio-
logic effect; and those who do not stop the medication
may not attribute any increased complications to it. This
may be due to a lack of understanding of the mechanism
of action of the drug and its effects. There is also the pos-
sibility that those who continue clopidogrel are more
meticulous with haemostasis due to knowledge of the
potential for increased complications. However we are
unable to draw any firm conclusions due to the small
sample size of our survey.
Our study indicates that there is a lack of uniformity
amongst orthopaedic surgeons, and haematologists in
Scotland, with regards the need to stop clopidogrel preop-
eratively. There also appears to be some confusion as to
whether additional DVT prophylaxis is needed. Most
orthopaedic units did not have a policy to deal with these
patients, and the majority did not contact the haematol-
ogy department at their hospital prior to instituting a pol-
icy on stopping clopidogrel. The majority of orthopaedic
surgeons also felt that further guidelines in this area
would be useful. In order to best manage these patients a
multidisciplinary approach is needed to fully assess risk of
bleeding compared to risk of an ischemic event when
assessing need for anticoagulation.
Our survey raises the following issues. First, is it safe to
continue taking clopidogrel in the perioperative period,
and if so, is any additional DVT prophylaxis needed or is
clopidogrel alone sufficient? Second, in the absence of any
current guidelines, are there medico-legal implications if
surgeons fail to conform to the British National Formu-
lary advice of stopping clopidogrel 7 days preoperatively?
Third, should elective/emergency surgery be delayed until
the antiplatelet effect of clopidogrel has worn off?
As this paper was an observational study, there are limita-
tions. Although more than 60% of consultants responded
there is the potential for bias as those who responded may
have more interest in this subject perhaps due to knowl-
edge of the medication or previous experience of compli-
cations. There is also the possibility that those who did
not respond do not stop the medication and experienced
complications. This would alter the results and therefore
the conclusions drawn. However the purpose of this study
was to audit the current practice in Scotland and highlight
a potential lack of uniformity and the need for further
guidance on peri-operative management of these patients.
Conclusion
This is an area of orthopaedic practice that requires further
research, as there is great variation in practice. At present
Table 3: Haematology Advice
Haematology Department Should clopidogrel be stopped If stopped when What DVT prophylaxis should be used
GRI No (if not on aspirin) N/A Clopidogrel
Yes (if on aspirin also) 7 days Aspirin
ERI Yes 2 – 3 days LMWH *
ARI Yes 3 days Fondaparinux if high risk otherwise none
Ninewells Yes 7 – 10 days LMWH if high risk otherwise none
* LMWH – Low Molecular Weight Heparin (eg. Enoxaparin/Clexane)Publish with BioMed Central    and   every 
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it appears that patients having elective surgery should ide-
ally stop clopidogrel 7 days in advance of surgery and that
if additional DVT prophylaxis is needed a LMWH or fon-
daparinux should be used. This should only be done once
the patients' condition has been discussed with a haema-
tologist and/or a cardiologist and the benefit/risk of anti-
coagulation considered. In the emergency setting
(trauma), patients need to be assessed on a case-by-case
basis. In situations where the risk of intra-operative bleed-
ing in patients taking clopidogrel is less than the morbid-
ity/mortality of delaying treatment, (e.g. fractured neck of
femur [16-18]), surgery should not be delayed. Surgeons
should be aware of the mechanism of action of clopidog-
rel and its potential side effects, and surgical technique
should be modified accordingly.
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